Nightstar Therapeutics plc is a clinical-stage gene therapy holding company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.
Company profile
Ticker
NITE
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Nightstar Therapeutics Ltd
SEC CIK
Corporate docs
NITE stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
17 Jun 19
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Jun 19
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Jun 19
8-K
Completion of Acquisition or Disposition of Assets
10 Jun 19
25-NSE
Exchange delisting
7 Jun 19
8-K
Update to Timetable Relating to the Acquisition by Biogen
29 May 19
10-Q
2019 Q1
Quarterly report
10 May 19
8-K
Nightstar Therapeutics PLC Shareholders Approve Scheme of
8 May 19
DEFA14A
Additional proxy soliciting materials
30 Apr 19
10-K/A
2018 FY
Annual report (amended)
30 Apr 19
Latest ownership filings
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
4 Feb 20
SC 13D/A
Nightstar Therapeutics plc
12 Jun 19
4
Change in insider ownership
11 Jun 19
4
DAVID M MOTT
7 Jun 19
4
Mohamad Makhzoumi
7 Jun 19
4
Seokho Bryan Yoon
7 Jun 19
4
Scott M Whitcup
7 Jun 19
4
Senthil Vel Sundaram
7 Jun 19
4
Gregory Scott Robinson
7 Jun 19
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|